New Results
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang
doi: https://doi.org/10.1101/2021.02.16.431305
Haolin Liu
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
Pengcheng Wei
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
Qianqian Zhang
2State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing 100193, People’s Republic of China
Zhongzhou Chen
2State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agriculture University, Beijing 100193, People’s Republic of China
Katja Aviszus
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
Walter Downing
3Department of Nursing, National Jewish Health, Denver, CO80206, USA
Shelley Peterson
3Department of Nursing, National Jewish Health, Denver, CO80206, USA
Lyndon Reynoso
4Department of Pharmacy, National Jewish Health, Denver, CO80206, USA
Gregory P. Downey
5Department of Medicine, National Jewish Health, Denver, CO 80206, USA
Stephen K. Frankel
5Department of Medicine, National Jewish Health, Denver, CO 80206, USA
John Kappler
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
Philippa Marrack
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA
Gongyi Zhang
1Department of Immunology and Genomic Medicine, National Jewish Health, Denver, CO 80206, USA and Department of Immunology and Microbiology, School of Medicine, Anschutz Medical Center, University of Colorado, Aurora, CO 80216, USA

Article usage
Posted February 16, 2021.
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang
bioRxiv 2021.02.16.431305; doi: https://doi.org/10.1101/2021.02.16.431305
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro
Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang
bioRxiv 2021.02.16.431305; doi: https://doi.org/10.1101/2021.02.16.431305
Subject Area
Subject Areas
- Biochemistry (9136)
- Bioengineering (6784)
- Bioinformatics (24001)
- Biophysics (12129)
- Cancer Biology (9534)
- Cell Biology (13778)
- Clinical Trials (138)
- Developmental Biology (7636)
- Ecology (11702)
- Epidemiology (2066)
- Evolutionary Biology (15513)
- Genetics (10644)
- Genomics (14327)
- Immunology (9483)
- Microbiology (22841)
- Molecular Biology (9090)
- Neuroscience (48995)
- Paleontology (355)
- Pathology (1482)
- Pharmacology and Toxicology (2570)
- Physiology (3846)
- Plant Biology (8331)
- Synthetic Biology (2296)
- Systems Biology (6192)
- Zoology (1301)